O

Ospedale Pediatrico Bambino Gesu | Dipartimento di Oncoematologia e Terapia Cellulare e Genica

Research site

(Unclaimed)

Location

Piazza Sant'Onofrio 4, Rome, Lazio, Italy

Site insights

Top conditions

Top treatments

Ataluren

ELX

Emapalumab

Tezacaftor

Elexacaftor

Ivacaftor

VX-445

Vancomycin

Ceftazidime

Pegcetacoplan

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting

Immunoglobulin A Nephropathy

Alport Syndrome

Drug: Atrasentan

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modifi...

Enrolling

Neoplasms

Genetic: Gene-modified (GM) T cell therapy

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).The partici...

Enrolling

Alagille Syndrome

Drug: Odevixibat

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting

Membranoproliferative Glomerulonephritis (MPGN)

Membranoproliferative Glomerulonephritis

Other: Placebo

Drug: Pegcetacoplan

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic fibrosis (CF) with at least 1...

Active, not recruiting

Cystic Fibrosis

Drug: ELX/TEZ/IVA

Drug: IVA